LENZ Therapeutics (LENZ) Interest Expenses (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Interest Expenses data on file, last reported at $716000.0 in Q1 2026.

• On a quarterly basis, Interest Expenses fell 44.88% year-over-year to $716000.0 in Q1 2026; TTM through Mar 2026 was $716000.0, a 44.88% decrease from a year earlier, with the FY2025 full-year figure at $70.3 million, up 26.6% from the prior year.
• Interest Expenses for Q1 2026 stood at $716000.0, up from $28000.0 in the prior quarter.
• Over the last five years, Interest Expenses for LENZ reached as high as $608.9 million in Q2 2022 and fell as low as -$4.6 million in Q4 2023.
• Historically, Interest Expenses has averaged $44.2 million across 5 years, with a median of $1.6 million in 2024.
• Across the five-year window, Interest Expenses plunged 315.45% in 2023 and soared 3068.29% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $2.1 million in 2022, then plunged by 315.45% to -$4.6 million in 2023, then jumped by 1302.75% to $55.5 million in 2024, then sank by 99.95% to $28000.0 in 2025, then surged by 2457.14% to $716000.0 in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $716000.0 in Q1 2026, $28000.0 in Q4 2025, and $1.0 million in Q3 2025.